Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Atherosclerosis Reports
Erschienen in: Current Atherosclerosis Reports 8/2022

14.06.2022 | Children/Adolescents/Young Adults and Atherosclerosis (D.P. Wilson, Section Editor)

Statins in Pregnancy: Can We Justify Early Treatment of Reproductive Aged Women?

verfasst von: Amelie Pham, Aleksandra Polic, Lynsa Nguyen, Jennifer L. Thompson

Erschienen in: Current Atherosclerosis Reports | Ausgabe 8/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Statins are the pillar of secondary prevention in reducing cardiovascular disease in high-risk adults. However, statin discontinuation is the standard recommendation in pregnant and lactating patients. This review evaluates whether we can justify the early treatment of reproductive aged women with statin therapy.

Recent Findings

Statins have several potential benefits including its antioxidant, anti-inflammatory, and anti-thrombogenic properties that may prevent the worsening of atherosclerosis in high-risk women. Nevertheless, most studies on statins and teratogenicity have a limited sample size and the effects of long-term statin use on fetal and neonatal health remain unknown. Not all statins may be safe and pravastatin’s cholesterol-lowering properties may be too limited to provide much maternal benefit in pregnancy.

Summary

While emerging evidence supports the use of pravastatin in pregnancy, we need to better assess the risk of early cardiovascular disease and acute progression of atherosclerosis before and during pregnancy to better understand the risks and benefits of statin use.
Literatur
1.
Mathews TJ, Hamilton BE. Mean age of mothers is on the rise: United States, 2000–2014. NCHS Data Brief. 2016;232:1–8.
2.
Mehta LS, Warnes CA, Bradley E, Burton T, Economy K, Mehran R, et al. Cardiovascular considerations in caring for pregnant patients: a scientific statement from the American Heart Association. Circulation. 2020;141(23):e884–903.PubMedCrossRef
3.
Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;316(19):2008–24.PubMedCrossRef
4.
Herrington W, Lacey B, Sherliker P, Armitage J, Lewington S. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circ Res. 2016;118(4):535–46.PubMedCrossRef
5.
6.
Okoth KCJ, Marshall T, Thangaratinam S, Thomas GN, Nirantharakumar K, Adderley NJ. Association between the reproductive health of young women and cardiovascular disease in later life: umbrella review. BMJ. 2020;371: m3963.
7.
Yao X, Shah ND, Gersh BJ, Lopez-Jimenez F, Noseworthy PA. Assessment of trends in statin therapy for secondary prevention of atherosclerotic cardiovascular disease in US adults from 2007 to 2016. JAMA Netw Open. 2020;3(11): e2025505.PubMedPubMedCentralCrossRef
8.
Karalis DG, Hill AN, Clifton S, Wild RA. The risks of statin use in pregnancy: A systematic review. J Clin Lipidol. 2016;10(5):1081–90.PubMedCrossRef
9.
Benschop L, Schalekamp-Timmermans S, Schelling SJC, Steegers EAP, Roeters van Lennep JE. Early pregnancy cardiovascular health and subclinical atherosclerosis. J Am Heart Assoc. 2019;8(15):e011394.PubMedPubMedCentralCrossRef
10.
Shah PK. Inflammation, infection and atherosclerosis. Trends Cardiovasc Med. 2019;29(8):468–72.PubMedCrossRef
11.
Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. Heart disease and stroke statistics–2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4):e25-146.PubMed
12.
13.
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–143.PubMed
14.
Kuklina EV, Carroll MD, Shaw KM, Hirsch R. Trends in high LDL cholesterol, cholesterol-lowering medication use, and dietary saturated-fat intake: United States, 1976–2010. NCHS Data Brief. 2013;117:1–8.
15.
Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart Disease and Stroke Statistics-2021 Update: a report from the American Heart Association. Circulation. 2021;143(8):e254–743.PubMedCrossRef
16.
17.
Germain AM, Romanik MC, Guerra I, Solari S, Reyes MS, Johnson RJ, et al. Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events? Hypertension. 2007;49(1):90–5.PubMedCrossRef
18.
Natland ST, Nilsen TI, Midthjell K, Andersen LF, Forsmo S. Lactation and cardiovascular risk factors in mothers in a population-based study: the HUNT-study. Int Breastfeed J. 2012;7(1):8.PubMedPubMedCentralCrossRef
19.
Baart SJ, Dam V, Scheres LJJ, Damen J, Spijker R, Schuit E, et al. Cardiovascular risk prediction models for women in the general population: a systematic review. PLoS ONE. 2019;14(1): e0210329.PubMedPubMedCentralCrossRef
20.
Russi G. Severe dyslipidemia in pregnancy: the role of therapeutic apheresis. Transfus Apher Sci. 2015;53(3):283–7.PubMedCrossRef
21.
Vrijkotte TG, Krukziener N, Hutten BA, Vollebregt KC, van Eijsden M, Twickler MB. Maternal lipid profile during early pregnancy and pregnancy complications and outcomes: the ABCD study. J Clin Endocrinol Metab. 2012;97(11):3917–25.PubMedCrossRef
22.
Hadden DR, McLaughlin C. Normal and abnormal maternal metabolism during pregnancy. Semin Fetal Neonatal Med. 2009;14(2):66–71.PubMedCrossRef
23.
Belo L, Caslake M, Gaffney D, Santos-Silva A, Pereira-Leite L, Quintanilha A, et al. Changes in LDL size and HDL concentration in normal and preeclamptic pregnancies. Atherosclerosis. 2002;162(2):425–32.PubMedCrossRef
24.
Sep S, Rijvers C, Smits L, van Bilsen M, Bekers O, Peeters L. Early-pregnancy changes in maternal lipid profile in women with recurrent preeclampsia and previously preeclamptic women with normal next pregnancy. Reprod Sci. 2011;18(10):998–1004.PubMedCrossRef
25.
Magnussen EB, Vatten LJ, Myklestad K, Salvesen K, Romundstad PR. Cardiovascular risk factors prior to conception and the length of pregnancy: population-based cohort study. Am J Obstet Gynecol. 2011;204(6):526.e1-8.CrossRef
26.
Catov JM, Bodnar LM, Kip KE, Hubel C, Ness RB, Harger G, et al. Early pregnancy lipid concentrations and spontaneous preterm birth. Am J Obstet Gynecol. 2007;197(6):610.e1-7.CrossRef
27.
Rohlfing AB, Nah G, Ryckman KK, Snyder BD, Kasarek D, Paynter RA, et al. Maternal cardiovascular disease risk factors as predictors of preterm birth in California: a case-control study. BMJ Open. 2020;10(6): e034145.PubMedPubMedCentralCrossRef
28.
Clausen T, Djurovic S, Henriksen T. Dyslipidemia in early second trimester is mainly a feature of women with early onset pre-eclampsia. BJOG. 2001;108(10):1081–7.PubMed
29.
Enquobahrie DA, Williams MA, Butler CL, Frederick IO, Miller RS, Luthy DA. Maternal plasma lipid concentrations in early pregnancy and risk of preeclampsia. Am J Hypertens. 2004;17(7):574–81.PubMedCrossRef
30.
Serrano NC, Guio-Mahecha E, Quintero-Lesmes DC, Becerra-Bayona S, Paez MC, Beltran M, et al. Lipid profile, plasma apolipoproteins, and pre-eclampsia risk in the GenPE case-control study. Atherosclerosis. 2018;276:189–94.PubMedCrossRef
31.
Demirci O, Tuğrul AS, Dolgun N, Sözen H, Eren S. Serum lipids level assessed in early pregnancy and risk of pre-eclampsia. J Obstet Gynaecol Res. 2011;37(10):1427–32.PubMedCrossRef
32.
Di Cianni G, Miccoli R, Volpe L, Lencioni C, Ghio A, Giovannitti MG, et al. Maternal triglyceride levels and newborn weight in pregnant women with normal glucose tolerance. Diabet Med. 2005;22(1):21–5.PubMedCrossRef
33.
Edison RJ, Berg K, Remaley A, Kelley R, Rotimi C, Stevenson RE, et al. Adverse birth outcome among mothers with low serum cholesterol. Pediatrics. 2007;120(4):723–33.PubMedCrossRef
34.
Ray JG, Diamond P, Singh G, Bell CM. Brief overview of maternal triglycerides as a risk factor for pre-eclampsia. BJOG. 2006;113(4):379–86.PubMedCrossRef
35.
Gratacós E, Casals E, Gómez O, Llurba E, Mercader I, Cararach V, et al. Increased susceptibility to low density lipoprotein oxidation in women with a history of pre-eclampsia. BJOG. 2003;110(4):400–4.PubMedCrossRef
36.
Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res. 2004;95(9):884–91.PubMedCrossRef
37.
Ahmed A, Williams DJ, Cheed V, Middleton LJ, Ahmad S, Wang K, et al. Pravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo-controlled trial. BJOG. 2020;127(4):478–88.PubMedCrossRef
38.
39.
Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478–90.PubMedPubMedCentralCrossRef
40.
De Castro-Orós I, Pocoví M, Civeira F. The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutations. Appl Clin Genet. 2010;3:53–64.PubMedPubMedCentral
41.
Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35(32):2146–57.PubMedPubMedCentralCrossRef
42.
Toft-Nielsen F, Emanuelsson F, Benn M. Familial hypercholesterolemia prevalence among ethnicities-systematic review and meta-analysis. Front Genet. 2022;13: 840797.PubMedPubMedCentralCrossRef
43.
Raal FJ, Hovingh GK, Catapano AL. Familial hypercholesterolemia treatments: guidelines and new therapies. Atherosclerosis. 2018;277:483–92.PubMedCrossRef
44.
Humphries SE, Cooper JA, Seed M, Capps N, Durrington PN, Jones B, et al. Coronary heart disease mortality in treated familial hypercholesterolaemia: update of the UK Simon Broome FH register. Atherosclerosis. 2018;274:41–6.PubMedPubMedCentralCrossRef
45.
Balla S, Ekpo EP, Wilemon KA, Knowles JW, Rodriguez F. Women living with familial hypercholesterolemia: challenges and considerations surrounding their care. Curr Atheroscler Rep. 2020;22(10):60.PubMedPubMedCentralCrossRef
46.
Amrock SM, Duell PB, Knickelbine T, Martin SS, O’Brien EC, Watson KE, et al. Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry. Atherosclerosis. 2017;267:19–26.PubMedCrossRef
47.
Cleary KL, Roney K, Costantine M. Challenges of studying drugs in pregnancy for off-label indications: pravastatin for preeclampsia prevention. Semin Perinatol. 2014;38(8):523–7.PubMedCrossRef
48.
US Food and Drug Administration (FDA). Content and format of labeling for human prescription drug and biological products; Requirements for pregnancy and lactation labeling. Federal Register. 2008;73(104):30831–68
49.
Zampelas A, Magriplis E. New insights into cholesterol functions: a friend or an enemy? Nutrients. 2019;11(7):1645
50.
Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998;19(1):26–37
51.
52.
Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19(1):117–25.PubMedCrossRef
53.
Dulak J, Jozkowicz A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets. 2005;5(8):579–94.PubMedPubMedCentralCrossRef
54.
Nanovskaya TN, Patrikeeva SL, Paul J, Costantine MM, Hankins GD, Ahmed MS. Transplacental transfer and distribution of pravastatin. Am J Obstet Gynecol. 2013;209(4):373 e1-5.CrossRef
55.
Manson JM, Freyssinges C, Ducrocq MB, Stephenson WP. Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. Reprod Toxicol. 1996;10(6):439–46.PubMedCrossRef
56.
Pollack PS, Shields KE, Burnett DM, Osborne MJ, Cunningham ML, Stepanavage ME. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. Birth Defects Res A Clin Mol Teratol. 2005;73(11):888–96.PubMedCrossRef
57.
Taguchi N, Rubin ET, Hosokawa A, Choi J, Ying AY, Moretti ME, et al. Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol. 2008;26(2):175–7.PubMedCrossRef
58.
Edison RJ, Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet A. 2004;131(3):287–98.PubMedCrossRef
59.
Petersen EE, Mitchell AA, Carey JC, Werler MM, Louik C, Rasmussen SA, et al. Maternal exposure to statins and risk for birth defects: a case-series approach. Am J Med Genet A. 2008;146A(20):2701–5.PubMedCrossRef
60.
61.
Mauricio R, Khera A. Statin use in pregnancy: is it time for a paradigm shift? Circulation. 2022;145(7):496–8.PubMedCrossRef
62.
US Food and Drug Administration (FDA). FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy; still advises most pregnant patients stop taking statins. FDA Drug Safety Communication. 2021. https://​www.​fda.​gov/​media/​150774/​download
63.
Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem. 1997;272(50):31725–9.PubMedCrossRef
64.
Vahedian-Azimi A, Karimi L, Reiner Z, Makvandi S, Sahebkar A. Effects of statins on preeclampsia: a systematic review. Pregnancy Hypertens. 2021;23:123–30.PubMedCrossRef
65.
Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1998;95(15):8880–5.PubMedPubMedCentralCrossRef
66.
Fox KA, Longo M, Tamayo E, Kechichian T, Bytautiene E, Hankins GD, et al. Effects of pravastatin on mediators of vascular function in a mouse model of soluble Fms-like tyrosine kinase-1-induced preeclampsia. Am J Obstet Gynecol. 2011;205(4):366 e1-5.CrossRef
67.
Cudmore M, Ahmad S, Al-Ani B, Fujisawa T, Coxall H, Chudasama K, et al. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation. 2007;115(13):1789–97.PubMedCrossRef
68.
Brownfoot FC, Tong S, Hannan NJ, Binder NK, Walker SP, Cannon P, et al. Effects of pravastatin on human placenta, endothelium, and women with severe preeclampsia. Hypertension. 2015;66(3):687–97 (discussion 445).PubMedCrossRef
69.
Grosser N, Hemmerle A, Berndt G, Erdmann K, Hinkelmann U, Schurger S, et al. The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells. Free Radic Biol Med. 2004;37(12):2064–71.PubMedCrossRef
70.
Lee TS, Chang CC, Zhu Y, Shyy JY. Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. Circulation. 2004;110(10):1296–302.PubMedCrossRef
71•.
Violi F, Calvieri C, Ferro D, Pignatelli P. Statins as antithrombotic drugs. Circulation. 2013;127(2):251–7 This study indicated that the lack of a reduction in cholesterol concentration in the fetuses exposed to pravastatin was reassuring enough to allow for larger clinical trials to proceed.PubMedCrossRef
72.••
Aggarwal PK, Chandel N, Jain V, Jha V. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia. J Hum Hypertens. 2012;26(4):236–41 This study indicated that pravastatin use in pregnancy could improve perinatal outcomes and stabilize maternal biomarkers of endothelial dysfunction before 20 weeks.PubMedCrossRef
73.
Costantine MM, Cleary K, Hebert MF, Ahmed MS, Brown LM, Ren Z, et al. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol. 2016;214(6):720 e1-e17.CrossRef
74.
Costantine MM, West H, Wisner KL, Caritis S, Clark S, Venkataramanan R, Stika C, Rytting E, Wang X, Ahmed M et al. A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia. Am J Obstet Gynecol. 2021;225(6):666.e1–e15
75.
Ahmed A, Williams DJ, Cheed V, Middleton LJ, Ahmad S, Wang K, et al. Pravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo-controlled trial. BJOG. 2020;127(4):478–88.PubMedCrossRef
76.
Aldika Akbar MI, Yosediputra A, Pratama RE, Fadhilah NL, Sulistyowati S, Amani FZ, Ernawati E, Dachlan EG, Angsar MD, Dukker G. INOVASIA study: a randomized open controlled trial to evaluate pravastatin to prevent preeclampsia and its effect on sFlt1/PlGF levels. Am J Perinatol. 2021.
Metadaten
Titel
Statins in Pregnancy: Can We Justify Early Treatment of Reproductive Aged Women?
verfasst von
Amelie Pham
Aleksandra Polic
Lynsa Nguyen
Jennifer L. Thompson
Publikationsdatum
14.06.2022
Verlag
Springer US
Erschienen in
Current Atherosclerosis Reports / Ausgabe 8/2022
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-022-01039-1

Weitere Artikel der Ausgabe 8/2022

Current Atherosclerosis Reports 8/2022 Zur Ausgabe

Coronary Heart Disease (S. Virani and M. Al Rifai, Section Editors)

Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know

Statin Drugs (R. Ceska, Section Editor)

LDL-C: The Only Causal Risk Factor for ASCVD. Why Is It Still Overlooked and Underestimated?

Evidence-Based Medicine, Clinical Trials and Their Interpretations (K. Nasir, Section Editor)

Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management

Coronary Heart Disease (S. Virani and M. Al Rifai, Section Editors)

SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?

Reviews and Scientific Meetings and New Research Implications (S. Virani, Section Editor)

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American College of Cardiology Scientific Sessions

Nutrition (K. Petersen, Section Editor)

Bioactives in the Food Supply: Effects on CVD Health

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise